share_log

Argenica Therapeutics Ltd: Patient Dosing Milestone Achieved in Phase 2 Stroke Trial

Apr 10 06:26
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.